Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
Adalimumab
Abbvie Pty Ltd
Medicine Registered
Humira Version 01 15 October 2009 Page 1 of 6 HUMIRA_ _VIAL Adalimumab (rch) CONSUMER MEDICINE INFORMATION _ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Humira. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT USING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. READ THIS LEAFLET CAREFULLY BEFORE YOU USE HUMIRA AND KEEP IT WITH THE MEDICINE. You may need to read it again. WHAT HUMIRA IS USED FOR Humira is intended for the treatment of • Rheumatoid arthritis, • Polyarticular Juvenile Idiopathic Arthritis, • Psoriatic arthritis, • Ankylosing spondylitis, • Crohn’s disease and • Psoriasis. The active ingredient in this medicine is adalimumab, a fully human monoclonal antibody. Monoclonal antibodies are proteins that recognise and bind to other unique proteins. Adalimumab binds to a specific protein (tumour necrosis factor or TNFalpha), which is present at increased levels in inflammatory diseases such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and psoriasis. • Rheumatoid Arthritis Humira is used to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis, a painful disease of the joints, as well as slow down and protect against damage to joints. Signs and symptoms of rheumatoid arthritis include joint pain, tenderness, swelling and stiffness. • Polyarticular Juvenile Idiopathic Art Διαβάστε το πλήρες έγγραφο
Humira Version 27 16 July 2013 Page 1 of 42 PRODUCT INFORMATION HUMIRA ® NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION Humira (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. Humira was created using phage display technology resulting in fully human heavy and light chain variable regions, which confer specificity to human tumour necrosis factor (TNF), and human IgG1 heavy chain and kappa light chain sequences. Humira binds with high affinity and specificity to soluble tumour necrosis factor (TNF-alpha) but not lymphotoxin (TNF-beta). Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Humira is supplied as a sterile, preservative-free solution of adalimumab for subcutaneous administration. The solution of Humira is clear and colourless with a pH of 5.2. The drug product is supplied as either a single-use pre-filled glass syringe, vial or as a single use, pre-filled pen (Humira Pen). Enclosed within the pen is a single-use, pre-filled glass syringe. All adult presentations contain 40mg adalimumab per 0.8 mL (50 mg/mL). The paediatric presentation contains 20mg adalimumab per 0.4 mL. Humira 40mg: Inactive ingredients include: 4.93 mg sodium chloride, 0.69 mg monobasic sodium phosphate dihydrate, 1.22 mg dibasic sodium phosphate dihydrate, 0.24 mg sodium citrate, 1.04 mg citric acid monohydrate, 9.6 mg mannitol, 0.8 mg polysorbate 80 a Διαβάστε το πλήρες έγγραφο